DNA polymerases are critically important enzymes and present targets for cancer chemotherapy that have not been adequately explored. Greater knowledge of the functions of individual eukaryotic DNA polymerases in DNA synthetic processes, and of their catalytic mechanisms, is significant for both fundamental biologic understanding and potential exploitation in cancer chemotherapeutic regimens. We propose here an investigation of eukaryotic DNA polymerases that takes advantage of our ability to create large libraries of mutant DNA polymerases with different catalytic properties.
In Specific Aim 1, we will identify mutants of DNA polymerases-d, -e, and -a that incorporate specific, mutagenic nucleotide analogs. We will analyze the roles of these polymerases in DNA metabolism by replacing the endogenous polymerases with the corresponding mutant enzymes. Incorporation of the analog and/or induction of diagnostic mutations in cells undergoing replication, repair or recombination will provide a signature for the participation of each polymerase in these processes.
In Specific Aim 2, we will utilize our new system for in vivo protein evolution to create novel DNA polymerase-6 mutants with enhanced capacity to copy DNA containing bulky lesions, and we will analyze the consequences of increased lesion bypass for cell survival and mutagenesis.
In Specific Aim 3, we will analyze the mechanisms by which DNA polymerases select complementary nucleotide substrates by creating and studying mutator and anti-mutator mutants. The proposed studies should facilitate exploitation of specific DNA polymerases as chemotherapeutic targets by providing knowledge relevant to inhibiting their catalytic activities and/or disrupting their functions in cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102029-04
Application #
7095901
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Okano, Paul
Project Start
2003-07-01
Project End
2008-04-30
Budget Start
2006-05-09
Budget End
2007-04-30
Support Year
4
Fiscal Year
2006
Total Cost
$325,571
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Beckman, Robert A; Loeb, Lawrence A (2017) Evolutionary dynamics and significance of multiple subclonal mutations in cancer. DNA Repair (Amst) 56:7-15
Fox, Edward J; Loeb, Lawrence A (2014) Cancer: One cell at a time. Nature 512:143-4
Kennedy, Scott R; Schmitt, Michael W; Fox, Edward J et al. (2014) Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc 9:2586-606
Shen, Jiang-Cheng; Fox, Edward J; Ahn, Eun Hyun et al. (2014) A rapid assay for measuring nucleotide excision repair by oligonucleotide retrieval. Sci Rep 4:4894
Fox, Edward J; Reid-Bayliss, Kate S; Emond, Mary J et al. (2014) Accuracy of Next Generation Sequencing Platforms. Next Gener Seq Appl 1:
Weedon, Michael N; Ellard, Sian; Prindle, Marc J et al. (2013) An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet 45:947-50
Kennedy, Scott R; Salk, Jesse J; Schmitt, Michael W et al. (2013) Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. PLoS Genet 9:e1003794
Fox, Edward J; Prindle, Marc J; Loeb, Lawrence A (2013) Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev 32:353-61
Prindle, Marc J; Schmitt, Michael W; Parmeggiani, Fabio et al. (2013) A substitution in the fingers domain of DNA polymerase ? reduces fidelity by altering nucleotide discrimination in the catalytic site. J Biol Chem 288:5572-80
Prindle, Marc J; Loeb, Lawrence A (2012) DNA polymerase delta in DNA replication and genome maintenance. Environ Mol Mutagen 53:666-82

Showing the most recent 10 out of 48 publications